Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986235 in healthy subjects
NCT03335553Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2017
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986235 in heart failure (HF) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of serious adverse events at 30 days, Number of deaths at 30 days and 3 more. Started Nov 2017; status: completed.
02
Drugs
BMS-986235
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03335553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03335553.